ArticleJCI insight2019
Human antibody response to Zika targets type-specific quaternary structure epitopes.
Article in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 62 citations in OpenAlex.
- Protective human antibodies against Powassan virus.Journal of virology · 2026Article
- Sub-neutralizing concentrations of Zika virus IgM monoclonal antibodies reduce IgG-mediated antibody-dependent enhancement of infectivity.bioRxiv : the preprint server for biology · 2026Article
- An ultrapotent human antibody neutralizes all maturation states of Zika virus.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Generation of a Human-Mouse Chimeric Anti-Japanese Encephalitis Virus and Zika Virus Monoclonal Antibody Using CDR Grafting.Microorganisms · 2025Article
- Estimating Zika Virus Seroprevalence in a Dengue Virus-Endemic Population: The Use of Blood Donors and Multiplex Serology to Monitor Arbovirus Outbreaks in the Dutch Caribbean.The Journal of infectious diseases · 2025Article
- Acute Febrile Illness Associated with an Emerging Dengue 4 GIIb Variant Causing Epidemic in León, Nicaragua 2022.Viruses · 2025Article
- Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage.Journal of virology · 2025Article
- Insect-specific virus platforms for arbovirus vaccine development.Frontiers in immunology · 2025Review
- Identification of B-cell epitopes of Indian Zika virus strains using immunoinformatics.Frontiers in immunology · 2025Article
- B cell receptor dependent enhancement of dengue virus infection.PLoS pathogens · 2024Article
- pr-independent biogenesis of infectious mature Zika virus particles.bioRxiv : the preprint server for biology · 2024Article
- Identification and characterization of a nonbiological small-molecular mimic of a Zika virus conformational neutralizing epitope.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Article
- A human monoclonal antibody isolated from Japanese encephalitis virus vaccine-vaccinated volunteer neutralizing various flaviviruses.Frontiers in microbiology · 2024Article
- Review
- A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.The Journal of infectious diseases · 2023Review
- Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody.Microbiology spectrum · 2023Article
- Antibody Immunity to Zika Virus among Young Children in a Flavivirus-Endemic Area in Nicaragua.Viruses · 2023Article
- Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
The recent Zika virus (ZIKV) epidemic in the Americas has revealed rare but serious manifestations of infection. ZIKV has emerged in regions endemic for dengue virus (DENV), a closely related mosquito-borne flavivirus. Cross-reactive antibodies confound studies of ZIKV epidemiology and pathogenesis. The immune responses to ZIKV may be different in people, depending on their DENV immune status. Here, we focus on the human B cell and antibody response to ZIKV as a primary flavivirus infection to define the properties of neutralizing and protective antibodies generated in the absence of preexisting immunity to DENV. The plasma antibody and memory B cell response is highly ZIKV type-specific, and ZIKV-neutralizing antibodies mainly target quaternary structure epitopes on the viral envelope. To map viral epitopes targeted by protective antibodies, we isolated 2 type-specific monoclonal antibodies (mAbs) from a ZIKV case. Both mAbs were strongly neutralizing in vitro and protective in vivo. The mAbs recognize distinct epitopes centered on domains I and II of the envelope protein. We also demonstrate that the epitopes of these mAbs define antigenic regions commonly targeted by plasma antibodies in individuals from endemic and nonendemic regions who have recovered from ZIKV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.